Comparison
Abacavir Hypersensitivity C5768819 vs 3m Syndrome 1 C2678312
Clinical comparison between Abacavir Hypersensitivity and 3M Syndrome 1 for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
3m Syndrome 1 C2678312
A genetic disorder causing severe short stature with distinctive facial features and skeletal abnormalities. Management involves monitoring growth and addressing orthopedic or other associated concerns.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
3m Syndrome 1 C2678312
0-0
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
3m Syndrome 1 C2678312
moderate
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
3m Syndrome 1 C2678312
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
3m Syndrome 1 C2678312
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
3m Syndrome 1 C2678312
musculoskeletal
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
3m Syndrome 1 C2678312
genetic
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 3m-syndrome-1-C2678312 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 3m Syndrome 1 C2678312 | Discriminating power |
|---|---|---|---|
| Timing of illness | Usually appears after abacavir exposure, often early in treatment; exact timing varies. | Present from birth or early childhood as a developmental pattern. | High |
| Growth and body habitus | Not primarily a growth disorder; acute systemic symptoms may occur. | Severe short stature with distinctive facial and skeletal features is characteristic. | High |
| Trigger | Linked to abacavir exposure and immune risk, including HLA-B*5701 status. | Genetic, not drug-triggered; no infectious or drug exposure is required. | High |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
New multisystem symptoms after starting abacavir
Temporal association with the drug favors a hypersensitivity reaction over a congenital syndrome.
High
Positive or unknown HLA-B*5701 status before abacavir
Screening identifies elevated risk and guides whether abacavir should be avoided.
High
Symptoms improve after supervised drug withdrawal
Resolution after stopping abacavir supports a drug reaction, but clinician confirmation is required.
Moderate
Choose 3m Syndrome 1 C2678312 when
Congenital severe short stature with facial and skeletal findings
This lifelong pattern fits 3M syndrome better than an acute drug reaction.
High
Family history or genetic testing suggesting 3M syndrome 1
A confirmed genetic diagnosis distinguishes it from an immunologic drug event.
High
No abacavir exposure and chronic orthopedic concerns
Absence of the drug trigger and a musculoskeletal course point away from hypersensitivity.
Moderate
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 3m Syndrome 1 C2678312 | Interpretation |
|---|---|---|---|
| HLA-B*5701 testing | Used before abacavir to identify people at higher reaction risk. | Not diagnostic for 3M syndrome. | A risk marker for abacavir reaction, not proof that symptoms are hypersensitivity. |
| Genetic testing for 3M syndrome | Not expected to establish abacavir hypersensitivity. | May support 3M syndrome 1 when clinically indicated. | Interpret variants with a genetics clinician; a result alone may not be definitive. |
| Growth and skeletal assessment | No characteristic congenital growth pattern is expected. | May show short stature and skeletal abnormalities over time. | Findings support clinical suspicion but do not replace genetic evaluation. |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- Often improves after abacavir is stopped, but severe reactions can occur and re-exposure may be hazardous.
- Factors
- Early recognition, permanent avoidance, and HIV treatment adjustment by a clinician.
3m Syndrome 1 C2678312
- Outcome
- A chronic genetic condition; growth and skeletal issues may persist despite supportive care.
- Factors
- Severity of skeletal findings, associated problems, and access to coordinated follow-up.
Time frame: Hours to weeks for a drug reaction; lifelong for 3M syndrome.
Correct diagnosis, avoidance of abacavir re-exposure, and individualized monitoring.
Complications comparison
| Complication | Presentation |
|---|---|
| Acute systemic reaction | Can be severe and may worsen if abacavir is continued or restarted. Not a typical feature of 3M syndrome. Suspected abacavir hypersensitivity needs urgent clinician review; do not restart independently. |
| Growth and orthopedic problems | Not the defining complication. Monitoring for growth, skeletal, and related concerns is central. Management is individualized; no single complication rate is established here. |
| Long-term course | Generally an acute event tied to drug exposure rather than a lifelong syndrome. A chronic congenital condition requiring ongoing surveillance. Prognosis depends on recognition, avoidance of re-exposure for the left, and supportive care for the right. |
Patient education highlights
- HighDo not restart abacavir
If hypersensitivity is suspected, stop only as directed and seek urgent care; restarting can be dangerous.
- HighDifferent conditions
A drug reaction and a congenital syndrome are not interchangeable diagnoses and need different specialists.
- MediumFollow-up
Report new symptoms promptly and keep genetic or medication records for clinician review.